Multiparametric Monitoring of Early Response to Antiangiogenic Therapy: A Sequential Perfusion CT and PET/CT Study in a Rabbit VX2 Tumor Model

Figure 4

Averaged flow-metabolic ratio (FMR) before and at different time points after bevacizumab therapy. FMR showed a distinct decreasing trend in the treatment group whereas no significant change was identified in the control group. In particular, FMR on day 7 and day 14 significantly decreased compared with baseline.